The science and technology of growing young — sergey young, founder, longevity vision fund.
Sergey Young (https://sergeyyoung.com/) is a longevity investor, visionary, and author, with a mission to help one billion people extend their healthy lifespans by making longevity affordable and accessible for everyone. As part of this mission, he is the Founder of the Longevity Vision Fund (LVF — https://lvf.vc/), a $100 Million venture capital fund that invests in technologies with the potential to disrupt life sciences and healthcare to help people live longer and healthier lives.
Sergey’s investment experience, spanning over 20 years, includes managing a $2 Billion private equity fund and co-founding Peak State Ventures, a New York-based private equity fund focusing on new technologies in Real Estate, Digital Healthcare, and the Future of Work. Sergey is also Longevity Venture Partner at BOLD Capital Partners, a $250 Million fund focusing on exponential technologies co-founded by Peter Diamandis.
Sergey’s longevity-related activities also include the following:
- Innovation Board Member at XPRIZE Foundation, dedicated to solving the world’s biggest problems; - Development Sponsor of Age Reversal XPRIZE, a global initiative designed to incentivize the development of technological breakthroughs to cure aging; - Board of Directors of American Federation of Aging Research (AFAR);
- Financial Advisory Board Member at All-Party Parliamentary Group (APPG) for Longevity, helping to shape national longevity strategy in the UK.
Sergey is also the author of an upcoming book, “The Science and Technology of Growing Young”. (https://www.amazon.com/Science-Technology-Growing-Young-Breakthroughs/dp/1950665879)
Papers referenced in the video: A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study. https://pubmed.ncbi.nlm.nih.gov/30596641/
Underlying features of epigenetic aging clocks in vivo and in vitro. https://onlinelibrary.wiley.com/doi/full/10.1111/acel.
Population Specific Biomarkers of Human Aging: A Big Data Study Using South Korean, Canadian, and Eastern European Patient Populations. https://pubmed.ncbi.nlm.nih.gov/29340580/
More TAME! The first part of this has a lot of result data.
Foresight Biotech & Health Extension Meeting sponsored by 100 Plus Capital. 2021 program & apply to join: https://foresight.org/biotech-health-extension-program/
Nir Barzilai, Albert Einstein School of Medicine. TAME Q&A: Lessons for Progress on Aging.
About Nir Barzilai: Nir Barzilai, MD, is a Professor in the Department of Endocrinology Medicine and the Department of Genetics at the Albert Einstein College of Medicine. He is also the Ingeborg and Ira Leon Rennert Chair of Aging Research at the Albert Einstein College of Medicine. Dr. Barzilai is the founding director of the Institute for Aging Research at Albert Einstein College of Medicine and the Director of the Nathan Shock Center for Excellence in the Basic Biology of Aging, funded by the National Institutes of Health (NIH); the center is coordinating 80 investigators and six program projects on the biology of aging. He is also the director of the Glenn Center of Excellence in the Biology of Human Aging. He is a chaired professor of medicine and of genetics and a member of the Diabetes Research Center and the divisions of endocrinology and geriatrics. Dr. Barzilai’s interests focus on several basic mechanisms in the biology of aging, including the biological effects of nutrients on extending life and the genetic determinants of life span. His team discovered many longevity gene in humans, and they further characterized the phenotype and genotype of humans with exceptional longevity through NIH awards. He also has an NIH Merit award investigating the metabolic decline that accompanies aging and its impact on longevity. Dr. Barzilai has published more than 270 peer-reviewed papers, reviews and chapters in textbooks. Dr. Barzilai serves on several editorial boards and advisory boards of pharmaceutical and start-up companies, and is a reviewer for numerous journals. A Beeson Fellow for Aging Research, Dr. Barzilai has received many other prestigious awards, including the Senior Ellison Foundation Award, the 2010 Irving S. Wright Award of Distinction in Aging Research, the NIA–Nathan Shock Award and a merit award from the NIA for his contributions in elucidating metabolic and genetic mechanisms of aging and was the 2018 recipient of the IPSEN Longevity award. He is leading the TAME (Targeting/Taming Aging with Metformin) Trial, a multi-center study to prove the concept that multi morbidities of aging can be delayed in humans and change the FDA indications to allow for next generation interventions. He is a founder of CohBar Inc. (now public company) and Medical Advisor for Life Biosciences. He is on the board of AFAR and a founding member of the Academy for Lifespan and Healthspan. He has been featured in major papers, TV programs, and documentaries (TEDx and TEDMED) and has been consulting or presented the promise for targeting aging at The Singapore Prime Minister Office, several International Banks, The Vatican, Pepsico, Milkin Institute, The Economist and Wired Magazine. His book, Age Later: Health Span, Life Span, and the New Science of Longevity, was published by St. Martin’s Press in June of 2020.
Join us: ► Twitter: https://twitter.com/foresightinst. ► Facebook: https://www.facebook.com/foresightinst. ► Instagram: https://www.instagram.com/existentialhope/ ► LinkedIn: https://www.linkedin.com/company/foresight-institute. ► Support to join: https://foresight.org/donate/membership/
Foresight Institute advances technologies for the long-term future of life, focusing on molecular machine nanotechnology, biotechnology, and computer science.
Follow us here for videos concerning our programs on Molecular Machines, Biotechnology & Health Extension, Intelligent Cooperation, and Existential Hope.
4:47 BioAge, 8:10 Church talking about how controlling aging is no longer speculative, 10:44 urging caution as they are not really talking about turning 67 year olds into 20 year olds. Near the end Church mentions A.I. an exponential possibilities of hitting all the pathways at once.
Recently, Avi Roy, alongside Nathan Cheng & Laura Minquini, hosted the second Longevity Panel discussion, which assembled some of the brightest minds working on reversing aging, and enhancing health and life span.
As with the first event, this discussion was intended to illuminate how they are approaching longevity and to know if we are any closer in achieving it.
The talk was split into two sections: the first being open discussion guided by questions from the hosts. The talk was then opened up to the floor, allowing audience questions. Part 1 will provide the transcript from the first section of the Longevity Panel. Enjoy!
You can check out the full transcript, with addition links on the Gowing Life website: https://www.gowinglife.com/longevity-panel-ii-the-scientists-working-on-reversing-aging-part-1/ ——————
The questions: 05:35 — How do you plan on reversing aging?
12:06 — How do we know that these therapies that are being developed in scientific labs or being brought to clinical trials, are actually having an effect on aging?
23:36 — This weekend Richard Branson went to space, while some of us saw a great feat of science and a 70 year old man accomplishing a lifelong dream, others saw a billionaire wasting money. Longevity also has this perception problem of being deemed another fancy of billionaires. Do you think it is important to change this and how do we do it?
I know that this is controversial in the longevity community, but there was overwhelming agreement among the dentists I talked with that mouthwash is excellent for preventing gingivitis (one study found that it was more effective than flossing) and reducing plaque.
Are you working to extend your healthspan and lifespan? Address the most common aging teeth problems with these dentist-approved tricks.
A summary of the sequel trial for a cocktail of drugs that originally turned back epigenetic clocks by 2.5 years. I do wonder what effect plasma filtering has on the thymus if any.
In this video we review the TRIIM study and look at the trial document for TRIIM-X, the extension study that Dr. Fahy is now conducting.
Timing — If you are familiar with the TRIIM Study please use the time links below to jump to TRIIM-X 0:12 : TRIIM Paper Review. 7:11 : TRIIM-X Trial Review. 08:59 : TRIIM vs TRIIM-X
Papers referred to in this video. Reversal of epigenetic aging and immunosenescent trends in humans Sept 2019 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826138/
Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial (TRIIM-X) https://clinicaltrials.gov/ct2/show/NCT04375657
******************************************** ~ NEW ~ Alive By Science — All products automatic 10% Discount Link — https://tinyurl.com/w8mk2zc. * Jinfiniti NAD, Senescent cell levels and other tests can be found here:* https://www.jinfiniti.com/products/ *** You can get a 10% discount by using the code ModernHealth. ********************************************
Health claims Disclosure: Information provided on this video is not a substitute for direct, individual medical treatment or advice. Please consult with your doctor first. Products or services mentioned in this video are not a recommendation.
Disclosure: Some of the links provided are affiliate links. Although we may receive a small commission from the affiliate, the cost of the product for you will always be the same, or often discounted. Thank you for supporting our channel.
Sirtuins are once again, making headlines. From a longer lifespan, again, through to helping old and dormant hair follicles to grow new hair, and of course a discourse between certain personalities on twitter, they continue to stimulate the interest and promise so much…
So I have decided to follow up my last sirtuins video with this one, Sirtuins revisited.
Here I look at them all from 1 to 7, to see what is being claimed for each one, and then I look at all the ways we can try to bring them all up to optimum so that we can live long, healthy lives, free from the maladies of old age.
I look at lifestyle interventions from exercise, saunas, cold therapies and more, through to diet choices and then finally on to supplements that are available to boost them all further.
So I hope you find it of use and enjoyable, and have a great weekend.
Sirtuins Anti Aging. Revisited.
Following up on my last sirtuins video I have added more information and an extensive list of what each sirtuin does, and what you can do to optimise yourself, and who you should be bothering.
My videos for more detail. Exercise https://youtu.be/ZMXFBgcuaaI Sleep https://youtu.be/iByq-KYVt3I Sauna https://youtu.be/dTwOMjWnzhg. Cold https://youtu.be/3C8F6gbVXyU Diet https://youtu.be/ZZ6ZfIulEoY Fasting https://youtu.be/OnjsALfx9Uc. Resveratrol https://youtu.be/uKfIShI7tpI Original Sirtuins https://youtu.be/cNUFesiescc.
Links to all articles I used to make the video.
Restoration of energy homeostasis by SIRT6 extends healthy lifespan https://www.nature.com/articles/s41467-021-23545-7 SIR2 blocks extreme life span extension. https://www.cell.com/fulltext/S0092-8674(05)00913-X Resveratrol not direct activator of SIRT1 https://pubmed.ncbi.nlm.nih.gov/20061378/ Dietary Activators of Sirt1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727669/ Sirt 1 Mitochondrial biogenesis. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403509/ Activation of thyroid T3 hormone. https://pubmed.ncbi.nlm.nih.gov/23922917/ Neurodegenerative diseases. https://pubmed.ncbi.nlm.nih.gov/21902666/ Insulin resistance/diabetes. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2753457/ Age-associated weight-gain. https://www.frontiersin.org/articles/10.3389/fendo.2015.00109/full. Liver function & body homeostasis. https://pubmed.ncbi.nlm.nih.gov/21638299/ Human embryonic stem cell differentiation. https://pubmed.ncbi.nlm.nih.gov/21144831/ Sirt 2 Lower mitochondrial activity & fatty acid metabolism. https://pubmed.ncbi.nlm.nih.gov/22302938/ Sirt 3 Oxidative stress. https://pubmed.ncbi.nlm.nih.gov/21658599/ Low levels of SIRT3 insulin resistance & fatty liver disease. https://portlandpress.com/biochemj/article-abstract/433/3/505/45501/Fatty-liver-is-associated-with-reduced-SIRT3?redirectedFrom=fulltext. Sirt 4 — Tumor-suppressive benefit. Mitochondrial glutamine metabolism and DNA damage. https://pubmed.ncbi.nlm.nih.gov/23562301/ Reduce insulin secretion. https://pubmed.ncbi.nlm.nih.gov/20729089/ Sirt 5 Mitochondrial metabolism &ammonia detoxification/removal. https://www.cell.com/cell/fulltext/S0092-8674(06)01020-8?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867406010208%3Fshowall%3Dtrue. Sirt 6 Genome stability & DNA repair. Low levels metabolic problems & age-related health issues. https://pubmed.ncbi.nlm.nih.gov/20729089/ Sirt 7 rDNA transcription & DNA repair mechanisms. https://www.cell.com/cell/fulltext/S0092-8674(06)01020-8?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867406010208%3Fshowall%3Dtrue. SIRT7 Old/dormant hair follicles. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507325/ Sirt1 overexpression calorie restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107309/#R70 Sirt1 moderate overexpression inflammation, liver cancer, diabetes &hepatic steatosis. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107309/#R71 Sirt6-overexpressing mice hypoxia & high-fat diet. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107309/#R74 SIRT6 highly fatal form of pancreatic cancer. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107309/#R75 Examples of NAD-boosting molecules include NMN, nicotinamide riboside. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107309/#R141 Inhibitors of CD38 such as apigenin142, quercetin142 & GSK https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107309/#R142 Omega 3 Lower inflammation & oxidative stress https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5032683/ Niacin energy metabolism https://www.sciencedaily.com/releases/2013/09/130930101836.htm. Elevate NAD levels in muscle, blood and other tissues. https://pubmed.ncbi.nlm.nih.gov/32386566/ Olive oil & sirtuins sirt 1 https://www.cell.com/molecular-cell/fulltext/S1097-2765(19)30894-9?rss=yes&utm_source=dlvr.it&utm_medium=twitter. Polyphenols & sirt 6 https://www.nature.com/articles/s41598-018-22388-5 Polyphenols & sirt 1 https://pubmed.ncbi.nlm.nih.gov/16603228/ Lifespan enhancing properties of sirt 2 — 1999 https://pubmed.ncbi.nlm.nih.gov/10521401/ Anti cancer properties. https://pubmed.ncbi.nlm.nih.gov/20450879/ DNA repair sirt 1 helping to repair the double helix https://pubmed.ncbi.nlm.nih.gov/18835033/ Sirt 1 role in cellular autophagy. https://www.pnas.org/content/105/9/3374 SIRT1 also supports mitochondrial autophagy, the detoxification of old cells & cellular renewal. Sirt & exercise. https://pubmed.ncbi.nlm.nih.gov/19549533/ High-intensity exercise or cold-exposure activates SIRT1 https://www.sciencedirect.com/science/article/pii/S1097276511009440 Sirt & circadian rhythms. https://science.sciencemag.org/content/342/6158/1243417?related-urls=yes&legid=sci;342/6158/1243417 Saunas increase NAD+ & SIRT1 levels. https://scholarcommons.usf.edu/etd/4567/ Cold exposure activate sirtuins. https://www.sciencedirect.com/science/article/pii/S1097276511009440
The University of Surrey has built an artificial intelligence (AI) model that identifies chemical compounds that promote healthy aging — paving the way towards pharmaceutical innovations that extend a person’s lifespan.
In a paper published by Nature Communication’s Scientific Reports, a team of chemists from Surrey built a machine learning model based on the information from the DrugAge database to predict whether a compound can extend the life of Caenorhabditis elegans — a translucent worm that shares a similar metabolism to humans. The worm’s shorter lifespan gave the researchers the opportunity to see the impact of the chemical compounds.
The AI singled out three compounds that have an 80 percent chance of increasing the lifespan of elegans:
Biofabrication technologies, including stereolithography and extrusion-based printing, are revolutionizing the creation of complex engineered tissues. The current paradigm in bioprinting relies on the additive layer-by-layer deposition and assembly of repetitive building blocks, typically cell-laden hydrogel fibers or voxels, single cells, or cellular aggregates. The scalability of these additive manufacturing technologies is limited by their printing velocity, as lengthy biofabrication processes impair cell functionality. Overcoming such limitations, the volumetric bioprinting of clinically relevant sized, anatomically shaped constructs, in a time frame ranging from seconds to tens of seconds is described. An optical-tomography-inspired printing approach, based on visible light projection, is developed to generate cell-laden tissue constructs with high viability (85%) from gelatin-based photoresponsive hydrogels. Free-form architectures, difficult to reproduce with conventional printing, are obtained, including anatomically correct trabecular bone models with embedded angiogenic sprouts and meniscal grafts. The latter undergoes maturation in vitro as the bioprinted chondroprogenitor cells synthesize neo-fibrocartilage matrix. Moreover, free-floating structures are generated, as demonstrated by printing functional hydrogel-based ball-and-cage fluidic valves. Volumetric bioprinting permits the creation of geometrically complex, centimeter-scale constructs at an unprecedented printing velocity, opening new avenues for upscaling the production of hydrogel-based constructs and for their application in tissue engineering, regenerative medicine, and soft robotics.
Mitochondrial Quality Control (Mitophagy), CNS Disorders, and Aging — Dr. Spring Behrouz, Ph.D., CEO, Vincere Biosciences Inc. / CEO, Neuroinitiative LLC.
Dr. Bahareh (Spring) Behrouz, PhD, is the CEO of Vincere Biosciences Inc (https://vincerebio.com/), a biotech company focused on developing novel, small molecule therapeutics targeting mitochondrial pathways and the improvement of mitochondrial quality.
Dr. Behrouz is also the CEO of NeuroInitiative, LLC (https://www.neuroinitiative.com/), a computational biology company she co-founded in 2014, which develops simulations of disease using their patented software platform. A core focus of her research at NeuroInitiative is on the elucidation of complex, converging pathways that contribute to the pathogenesis of Parkinson’s disease (PD), a neuro-degenerative brain disorder which dramatically effects movement, which nearly one million people in the U.S. are living with, and 10 million patients worldwide.
Dr. Behrouz received her graduate training at Michigan State University in the laboratory of Dr. John Goudreau and studied differential susceptibility of dopaminergic neuron sub-types in models of PD. She completed her post-doctoral training in the laboratory of Dr. Matthew Farrer at the Mayo Clinic in Jacksonville, where she primarily focused on in-vivo and primary culture models of LRRK2-mediated pathogenesis and was part of the team that discovered a new pathogenic mutation in VPS35.
